ELAB

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

PMGC Eyes ELAB EL-22/EL-32 in Space Microgravity Study

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>PMGC unveils a three-part strategy with Orbit2Orbit to fuse microgravity research, U.S. manufacturing, and strategic equity. NorthStrive Bio would test EL-22 and EL-32 in Orbit2Orbit&#039;s platform, potentially validating muscle-preservation tech. A&amp;B Aerospace would supply U.S. flight hardware, with a CAD 200k investment as Orbit2Orbit moves toward a Canadian listing.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>PMGC (ELAB) signs a non-binding term sheet with Orbit2Orbit for a three-part space platform.</li><li>Mice2Space would evaluate EL-22/EL-32 in microgravity for muscle preservation.</li><li>A&amp;B Aerospace to be Orbit2Orbit&#039;s U.S. manufacturing partner; CAD $200k investment planned.</li><li>Deal is non-binding; definitive agreements, due diligence, and milestones remain uncertain.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>PMGC Holdings Inc. (ELAB)</strong>: Exploring a three-part strategic relationship with Orbit2Orbit; potential upside for ELAB&#039;s NorthStrive assets.</li><li><strong>NorthStrive Biosciences Inc. (N/A)</strong>: PMGC subsidiary; EL-22 and EL-32 are its lead candidates being tested in microgravity.</li><li><strong>Orbit2Orbit Pty Ltd (N/A)</strong>: Australian spaceflight platform; private company forming ties with PMGC for research and manufacturing.</li><li><strong>A&amp;B Aerospace, Inc. (N/A)</strong>: PMGC subsidiary; would be Orbit2Orbit&#039;s preferred U.S. manufacturing partner.</li><li><strong>Credissential Inc. (WHIP)</strong>: Proposed reverse takeover listing linked to Orbit2Orbit; potential price/flow catalyst if proceeds.</li></ul>
  </section>

  <section data-block="category">
    <h3>M&amp;A</h3>
    <p>Category: M&amp;A. The news describes a strategic collaboration and potential equity investment across PMGC&#039;s platform, combining biotech assets with aerospace manufacturing and a future listing pathway. It reflects corporate development activity that could influence ELAB sentiment via ELAB’s link to EL-22/EL-32 and associated partnerships.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Non-binding term sheet signals potential strategic expansion for PMGC&#039;s platform.</li><li>ELAB-linked EL-22/EL-32 data in microgravity could lift ELAB valuation.</li><li>Orbit2Orbit&#039;s CSE listing via reverse takeover may unlock liquidity and catalysts.</li><li>US manufacturing tie-up with A&amp;B Aerospace could broaden PMGC&#039;s production footprint.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date of release: Aug 25, 2026.</li><li>CAD $200,000 PMGC investment in Orbit2Orbit at CAD $0.80 per share.</li><li>Orbit2Orbit aims for Canadian Securities Exchange listing via reverse takeover.</li><li>NorthStrive Bio&#039;s EL-22 and EL-32 to be evaluated in microgravity.</li><li>A&amp;B Aerospace to serve as Orbit2Orbit&#039;s U.S. manufacturing partner.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish on ELAB over 12–24 months if EL-22/EL-32 microgravity data unlock upside; near-term catalysts are definitive agreements and milestone progress.</p>
  </section>
</section>


<article>
  <p><em>Proposed Mice2Space spaceflight study would evaluate EL-22 and EL-32 in mice in a real-world microgravity environment, targeting one of the most significant physiological challenges of spaceflight</em></p>
  <p><em>Three-part relationship would expand PMGC’s footprint in the growing commercial space economy through a preferred U.S. manufacturing role for A&amp;B Aerospace and a planned strategic investment in Orbit2Orbit</em></p>

  <p>Newport Beach, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: <strong>ELAB</strong>) ("PMGC" or the "Company") is pleased to announce that it has entered into a non-binding term sheet with Orbit2Orbit Pty Ltd ("Orbit2Orbit" or "O2O"), an Australia-headquartered space technology company, outlining a proposed multi-part strategic relationship spanning space-based bioscience research, aerospace manufacturing, and a strategic investment by PMGC that would further expand the Company’s exposure to the growing commercial space economy.</p>

  <p>The proposed relationship is intended to combine capabilities across PMGC’s operating businesses with Orbit2Orbit’s spaceflight platform and its Mice2Space live-animal research capability, creating a differentiated framework to support biological research in microgravity while establishing a potential U.S.-based manufacturing relationship for future Orbit2Orbit space systems.</p>

  <p>Under the term sheet, the parties are contemplating three principal transactions:</p>

  <section>
    <h2><strong>Mice2Space Microgravity Research Collaboration</strong></h2>
    <p>NorthStrive Biosciences Inc. ("NorthStrive Bio"), a wholly owned subsidiary of PMGC, and Orbit2Orbit intend to collaborate on the development and use of the Mice2Space live-animal research capability utilizing the Orbit2Orbit platform. NorthStrive Bio’s study would evaluate its lead therapeutic candidates, <strong>EL-22</strong> and <strong>EL-32</strong>, in mice for muscle retention and body composition outcomes in microgravity compared with Earth-based controls.</p>

    <p>Muscle atrophy is one of the most significant physiological challenges associated with prolonged exposure to microgravity, and the Company believes spaceflight offers a compelling environment for evaluating muscle-preservation therapeutics. The Company believes that evaluating <strong>EL-22</strong> and <strong>EL-32</strong> in a true spaceflight environment could provide important insights into the assets’ muscle-preservation profile while expanding the potential applications of NorthStrive Bio’s intellectual property, including potential relevance to Earth-based conditions involving muscle loss.</p>

    <p>Orbit2Orbit is expected to lead the design, development, prototyping, and engineering of the Mice2Space payload enclosure and associated systems in Australia, and NorthStrive Bio would lead the design, execution, and analysis of its scientific study. A&amp;B Aerospace, Inc. ("A&amp;B Aerospace"), a wholly owned aerospace manufacturing subsidiary of PMGC, would support manufacture of the final flight hardware in the United States, as further described below.</p>

    <p>NorthStrive Bio would retain ownership of the intellectual property in its study protocols, preclinical data, and results. Orbit2Orbit would retain ownership of the Mice2Space platform, payload architecture, and related systems.</p>
  </section>

  <section>
    <h2><strong>U.S. Aerospace Manufacturing Partnership</strong></h2>
    <p>The term sheet also contemplated A&amp;B Aerospace serving as Orbit2Orbit’s preferred U.S.-based manufacturing partner under a definitive agreement.</p>

    <p>A&amp;B Aerospace would provide precision machining, fabrication, and manufacturing services for Orbit2Orbit’s prototypes, flight hardware, spacecraft components, payload interfaces, ground support equipment, and such other products and assemblies as may be mutually agreed, including final hardware for the Mice2Space program. A&amp;B Aerospace would also support the transportation and logistics required to move Mice2Space payload hardware to applicable pre-flight qualification and environmental testing.</p>

    <p>The Company believes the proposed relationship directly advances PMGC’s strategy of expanding the capabilities and customer base of its U.S. aerospace manufacturing operations while increasing its exposure to the rapidly growing commercial space industry, and would build on A&amp;B Aerospace’s AS9100- and ISO 9001-certified precision manufacturing platform.</p>
  </section>

  <section>
    <h2><strong>Strategic Investment in Orbit2Orbit</strong></h2>
    <p>As part of the proposed relationship, PMGC intends to subscribe for CAD <strong>200,000</strong> of Orbit2Orbit common shares at CAD <strong>0.80</strong> per share in connection with Orbit2Orbit’s current private placement financing and proposed listing on the Canadian Securities Exchange through a reverse takeover transaction. The planned investment is intended to align PMGC with Orbit2Orbit’s growth as the space technology company pursues its proposed public listing.</p>

  </section>

  <section>
    <h2><strong>A Platform-Wide Opportunity</strong></h2>
    <p>PMGC believes the proposed relationship showcases the strength of the PMGC platform model, with the businesses within the platform working together to pursue opportunities at the intersection of aerospace manufacturing, space technology, and biotechnology. NorthStrive Bio is developing therapeutic assets focused on preserving muscle, while the Company’s aerospace operations provide sophisticated U.S.-based manufacturing capabilities. Orbit2Orbit presents an opportunity to bring those capabilities together within a real-world spaceflight research platform, with each of the three proposed transactions aligned with an existing PMGC operating strength and intended to reinforce the others.</p>

    <p>The proposed transactions remain subject to customary due diligence, negotiation and execution of definitive agreements, applicable corporate approvals and other customary closing conditions. Project costs, timelines, deliverables, and milestones remain subject to further collaboration and agreement between the parties.</p>

    <p>The term sheet is non-binding and remains subject to the negotiation and execution of definitive agreements and completion of conditions precedent. There can be no assurance that the parties will enter into definitive agreements on the terms contemplated by the term sheet, or at all, or that the proposed transactions will be consummated. Even if definitive agreements are entered into, there can be no assurance as to the timing or ultimate completion of the proposed transactions. The terms of any definitive agreements, if executed, may differ materially from those described in the term sheet or this press release.</p>
  </section>

  <section>
    <h2><strong>About PMGC Holdings Inc.</strong></h2>
    <p>PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.</p>
  </section>

  <section>
    <h2><strong>About NorthStrive Biosciences Inc.</strong></h2>
    <p>NorthStrive Biosciences Inc., a PMGC Holdings Inc. (NASDAQ: <strong>ELAB</strong>) company, is a biopharmaceutical company focused on the development and acquisition of therapeutics for the preservation of lean muscle mass. Its lead product candidates are <strong>EL-22</strong>, an engineered probiotic targeting myostatin, and <strong>EL-32</strong>, an engineered probiotic targeting both myostatin and activin A, proteins that negatively regulate skeletal muscle growth. Both are being developed to help patients preserve lean muscle mass during GLP-1 receptor agonist and other obesity-related weight loss treatment. For more information, please visit www.northstrivebio.com.</p>
  </section>

  <section>
    <h2><strong>About A&amp;B Aerospace, Inc.</strong></h2>
    <p>Founded in 19...</p>
  </section>

  <section>
    <h2><strong>Important Notice</strong></h2>
    <p>The term sheet is non-binding and remains subject to the negotiation and execution of definitive agreements and completion of conditions precedent. There can be no assurance that the parties will enter into definitive agreements on the terms contemplated by the term sheet, or at all, or that the proposed transactions will be consummated. Any definitive agreements may differ materially from those described herein or in this release.</p>
  </section>

  <ul>
    <li><strong>Stock symbol:</strong> <strong>ELAB</strong> (NASDAQ)</li>
    <li><strong>Lead assets:</strong> EL-22 and EL-32</li>
    <li><strong>Strategic investment:</strong> CAD $200,000 of Orbit2Orbit common shares at CAD $0.80 per share</li>
    <li><strong>Manufacturing partnership:</strong> A&amp;B Aerospace as Orbit2Orbit’s preferred U.S.-based manufacturing partner</li>
    <li><strong>Platform scope:</strong> Space-based bioscience, aerospace manufacturing, and biotechnology alignment</li>
  </ul>
</article>

PMGC unveils a three-part strategy with Orbit2Orbit to fuse microgravity research, U.S. manufacturing, and strategic equity. NorthStrive Bio would test EL-22 and EL-32 in Orbit2Orbit's platform, potentially validating muscle-preservation tech. A&B Aerospace would supply U.S. flight hardware, with a CAD 200k investment as Orbit2Orbit moves toward a Canadian listing.

pmgc-holdings-announces-term-sheet-with-orbit2orbit-for-northstrive-biosciences-to-launch-a-spaceflight-study-of-its-myostatin-and-activin-a-assets-el-22-and-el-32-targeting-microgravity-induced-muscle-loss

News insight

PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

AI summary

Sentiment rationale

Key facts

M&A